trial

Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders

NCTId NCT01519557
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Early Phase 1 · Completed
Enrollment 68 (actual)
Sponsored by New York State Psychiatric Institute, Washington Heights Community Service
Primary completion 2013-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Early Phase 1
Status
Completed
Enrollment
68 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2011-04
Primary completion
2013-08
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
DAR-100A

Sponsors

New York State Psychiatric Institute, Washington Heights Community ServiceLead Sponsor

Investigators

1
Jeffrey A Lieberman, M.D.Principal Investigator

Sites

1 total
New York, United States

Facts & assertions

4 sourced
Enrollment
68
Phase
EARLY_PHASE1
Primary Completion Date
2013-08
Status
COMPLETED
relationships
The graph out of here
drug
DAR-100A
drug
lead_sponsor
New York State Psychiatric Institute, Washington Heights Community Service
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Jeffrey A Lieberman, M.D.
person